Royal Bank of Canada Lowers Dr. Martens (LON:DOCS) Price Target to GBX 6,000

Dr. Martens (LON:DOCS) had its price target cut by equities researchers at Royal Bank of Canada from GBX 7,000 ($93.50) to GBX 6,000 ($80.14) in a report issued on Monday,Digital Look reports. The firm presently has a “sector perform” rating on the stock.

Dr. Martens Trading Up 1.8%

Shares of DOCS traded up GBX 1.05 ($0.01) during trading hours on Monday, hitting GBX 58.20 ($0.78). 549,293 shares of the stock were exchanged, compared to its average volume of 2,313,506. The firm has a market capitalization of £564.98 million, a P/E ratio of 8.25, a price-to-earnings-growth ratio of 6.40 and a beta of 0.11. Dr. Martens has a fifty-two week low of GBX 43.02 ($0.57) and a fifty-two week high of GBX 93.25 ($1.25). The business has a 50-day moving average of GBX 53.38 and a 200-day moving average of GBX 62.53. The company has a debt-to-equity ratio of 127.27, a current ratio of 2.85 and a quick ratio of 1.13.

Insider Buying and Selling at Dr. Martens

In related news, insider Giles Wilson purchased 32,640 shares of Dr. Martens stock in a transaction on Tuesday, March 25th. The shares were bought at an average cost of GBX 54 ($0.72) per share, for a total transaction of £17,625.60 ($23,541.61). In the last ninety days, insiders have purchased 33,206 shares of company stock valued at $1,792,771. 4.36% of the stock is currently owned by company insiders.

About Dr. Martens

Dr. Martens is an iconic British brand founded in 1960 in Northamptonshire. Originally produced for workers looking
for tough, durable boots, the brand was quickly adopted by diverse youth subcultures and associated musical
movements. Dr. Martens have since transcended their working-class roots while still celebrating their proud heritage
and, six decades later, “Docs” or “DMs” are worn by people around the world who use them as a symbol of
empowerment and their own individual attitude.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.